Leading companies are revolutionizing medicine by turning B cells into miniature drug factories. Engineered B cell therapies allow genetically encoded drugs to be produced in the laboratory, eliminating the need for immunosuppressants or lymphodepletion therapies. This is a breakthrough that promises a safer and more effective approach to delivering therapeutic proteins for a variety of conditions.
Currently, clinical-stage programs using this technology are limited (see Table 1 of this article). However, these improvements are critical to unlocking the full potential of B cell factories. Scientists are taking advantage of the long-lived nature of these cells to improve the production and delivery of therapeutic proteins.
Read more: NATURE
The potential of this technology is huge, offering solutions that overcome the limitations of traditional treatments such as enzyme replacement therapy, antibody therapy, gene therapy, and many other types of cell therapy. Stay tuned for the latest information from these groundbreaking programs that will shape the future of medical innovation!
Check out the page: STEMCELL Technologies - https://www.stemcell.com/product-portfolios/b-cell-research/cell-sourcing.html
